We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of polymerised type I collagen on hyperinflammation of adult outpatients with symptomatic COVID‐19.
- Authors
Méndez‐Flores, Silvia; Priego‐Ranero, Ángel; Azamar‐Llamas, Daniel; Olvera‐Prado, Héctor; Rivas‐Redonda, Kenia Ilian; Ochoa‐Hein, Eric; Perez‐Ortiz, Andric; Rendón‐Macías, Mario E.; Rojas‐Castañeda, Estefano; Urbina‐Terán, Said; Septién‐Stute, Luis; Hernández‐Gilsoul, Thierry; Aguilar‐Morgan, Adrián Andrés; Fernández‐Camargo, Dheni A.; Olivares‐Martínez, Elizabeth; Hernández‐Ramírez, Diego F.; Torres‐Villalobos, Gonzalo; Furuzawa‐Carballeda, Janette
- Abstract
On day 1 after the last PTIC or placebo administration, the IP-10 levels decreased 75% in the PTIC group ( I p < i .001) and 40% in the placebo group ( I p = i .015) vs. baseline; this reduction was greater in the former group than in the latter ( I p = i .0047; Figure 1A and F). At day 8 post-treatment, 2 of 81 patients (2.5%) received supplemental oxygen via nasal cannula: 1/42 (2.3%) of the PTIC group (one patient received 2 L/min) and 1/39 (2.6) of the placebo group (4 L/min). Although dexamethasone is approved for the hyperinflammation treatment of hospitalised COVID-19 patients, non-hospitalised patients do not benefit from this therapy.1 A potential drug for treating COVID-19 patients is polymerised type I collagen (PTIC).
- Subjects
INFLAMMATION; COLLAGEN
- Publication
Clinical & Translational Medicine, 2022, Vol 12, Issue 3, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.763